Health insurance; requirements for certain opioid antagonists.

Removed internal legislative markers such as 'Senate Substitute', bill tracking numbers, and committee attribution that were present in the working draft.

Added official chapter designation (Chapter 423), the approval date (April 8, 2026), and standard header formatting required for published laws.

Adjusted text formatting to align with the official style of the Code of Virginia, including consistent indentation and line breaks, though the legal text itself is identical.

The document structure changed from a standard bill format to a 'House Substitute' format, including new page numbers (e.g., 26107033D) and altered line breaks, but no legal content was added, removed, or modified.

The document format changed from a final 'Enrolled' act to a 'Labor and Commerce Substitute' amendment, indicating the bill is now a proposal for further legislative review rather than a finalized law.

Insurers are now required to cover at least one nonprescription opioid antagonist used for overdose reversal, in addition to the existing requirement for prescription antagonists.

Cost-sharing for nonprescription opioid antagonists is now explicitly capped to not exceed the cost-sharing amount for the covered prescription opioid antagonist.

The bill was amended to include a new section clarifying the statutory construction and relationship of the new opioid coverage provisions to other existing insurance laws.

The bill's status changed from 'Introduced' to 'Enrolled', indicating it has been passed by both legislative chambers and signed into law.

The specific section number in the Code of Virginia was updated from 38.2-3412.2 to 38.2-3407.18:1 to reflect its final placement in the statutory code.

The bill text was reformatted to align with the official 'Enrolled' document style, including adding the 'Virginia Acts of Assembly' header and approval date.

A new subsection was added stating that if this coverage is included in the state's essential health benefits benchmark plan, the mandate does not apply to the individual and small group markets.